Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aakaar Medical TechnologiesNSE:AAKAAR +2.17%21 Debt-to-EBITDA is 0.85 as of Mar. 2026, which is 50% below its 10-year median of 1.69. GuruFocus rates NSE:AAKAAR with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Aakaar Medical Technologies ranks worse than 51.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aakaar Medical Technologies's Debt-to-EBITDA or its related term are showing as below:
NSE:AAKAAR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.59 Med: 1.69 Max: 3
Current: 1.69
During the past 5 years, the highest Debt-to-EBITDA Ratio of Aakaar Medical Technologies was 3.00. The lowest was 1.59. And the median was 1.69.
NSE:AAKAAR's Debt-to-EBITDA is ranked worse than 51.79% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs NSE:AAKAAR: 1.69
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aakaar Medical Technologies Debt-to-EBITDA Related Terms
Aakaar Medical Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AAKAAR vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Aakaar Medical Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aakaar Medical Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aakaar Medical Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aakaar Medical Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Aakaar Medical Technologies (NSE:AAKAAR) has a Debt-to-EBITDA of 0.85 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aakaar Medical Technologies. This is 50% below median its historical median of 1.69. Over the past decade, Aakaar Medical Technologies' Debt-to-EBITDA has ranged from 1.59 to 3.00. According to the industry distribution chart, Aakaar Medical Technologies ranks #246 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 51.8%.
Is Aakaar Medical Technologies' Debt-to-EBITDA too high?
Aakaar Medical Technologies' current Debt-to-EBITDA of 0.85 is 50% below median its 10-year median of 1.69. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 3.00. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Aakaar Medical Technologies' value of 0.85 is 47.9% below this industry median. Based on the distribution chart, Aakaar Medical Technologies ranks #246 out of 475 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aakaar Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Aakaar Medical Technologies' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aakaar Medical Technologies ranks #246 out of 475 companies for Debt-to-EBITDA. This places Aakaar Medical Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Aakaar Medical Technologies' value of 0.85 is 47.9% below this benchmark. Historically, Aakaar Medical Technologies' own Debt-to-EBITDA has ranged from 1.59 to 3.00 over the past decade. While the company's 10-year median is 1.69 vs. the industry median of 1.63, Aakaar Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aakaar Medical Technologies's current Debt-to-EBITDA of 0.85 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aakaar Medical Technologies. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aakaar Medical Technologies's current Debt-to-EBITDA is 0.85, which is 50% below median its own 10-year median of 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aakaar Medical Technologies stock overvalued right now?
Aakaar Medical Technologies (NSE:AAKAAR) has a current Debt-to-EBITDA of 0.85. The current Debt-to-EBITDA is 0.85, which is 50% below median its 10-year median of 1.69 and 47.9% below the Medical Devices & Instruments industry median of 1.63. Aakaar Medical Technologies' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aakaar Medical Technologies (NSE:AAKAAR), the current Debt-to-EBITDA is 0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aakaar Medical Technologies Ltd is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It has established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business(B2B) channels for product distribution and sales. The company supply its products & devices to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments.
21GF Score
Get the complete analysis for NSE:AAKAAR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AAKAAR has been successfully added to your 
